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Irritable bowel syndrome (IBS) is a functional bowel disorder, most likely with multiple 
interacting factors contributing to its aetiology. The intestinal microbiota has been 
proposed as one of these factors, with a putative role in the development or maintenance 
of IBS symptoms. The human intestinal microbiota is a rich and dynamic microbial 
community inhabited by 1014 bacteria, most of which are uncultivable. Therefore, to 
obtain a reliable general view of the resident bacteria and to detect specifi c bacterial 
phylotypes theoretically without restrictions, the use of molecular methods capable of 
detecting the uncultivable microbes is essential. 
Real-time polymerase chain reaction (real-time PCR) technology was assessed 
for the quantifi cation of bacteria from faecal samples, and 43 assays were designed for 
quantifying resident, pathogenic, probiotic or IBS-related bacteria or bacterial phylotypes. 
With real-time PCR, a 0.01% subpopulation could be quantifi ed from mixed faecal 
deoxyribonucleic acid (DNA) samples, with a linear range of fi ve orders of magnitude. 
The method proved to be sensitive and accurate also with intact bacterial cells spiked to 
faecal samples.
The intestinal microbiota of subjects suffering from IBS was then compared with 
that of healthy controls using DNA-based methods. For comparing the microbiotas 
on a scale covering the entire community, genomic microbial DNA extracted from 
faecal samples was pooled according to symptom subtype (diarrhoea-predominant, 
constipation-predominant, mixed-subtype) and percent guanine plus cytosine (G+C) 
profi led. The three most diverging %G+C fractions were analysed by cloning and partial 
sequencing of the 16S ribosomal ribonucleic acid (rRNA) gene. The 16S rRNA gene 
sequences were used to compare differences in the subject groups in more detail. The 
clone libraries on the whole diverged from each other, and several differences were 
detected in the abundances of sequences within certain phylotypes or closely related 
phylotypes between various pooled samples. Sequences affi liating with the genera 
Coriobacterium and Collinsella within the phylum Actinobacteria were considerably 
more abundant in the pooled healthy control sample.
To analyse the quantities of these putatively IBS-associated phylotypes within 
individual samples, real-time PCR was applied. Several signifi cant differences were 
detected, including a novel clostridial 16S rRNA gene phylotype associated with mixed-
subtype IBS (IBS-M) and healthy controls and a Ruminococcus torques resembling 
phylotype associated with diarrhoea-predominant IBS (IBS-D). IBS-D patients diverged 
from constipation-predominant (IBS-C) and IBS-M patients and the healthy controls, 
in a multivariate analysis of 14 quantifi ed phylotypes. It should be noted, however, that 
these results give no indication as to whether the observed alterations in the intestinal 
microbiotas of IBS patients are a causative agent in IBS aetiology or merely a result of 
the altered environment in the disturbed gut.
In conclusion, the intestinal microbiotas of IBS patients and healthy controls were 
found to differ from each other. These results support the hypothesis of intestinal bacteria 
having a role in IBS, and the specifi c phylotype-level differences detected warrant further 
studies for their potential use in IBS diagnostics, therapeutic trial follow-up and host-
microbe interactions.
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1. Introduction
Food is digested, nutrients are absorbed and waste material is excreted through the 
gastrointestinal (GI) tract. Within the GI tract, a diverse and dynamic self-replicating 
entity essential for healthy existence resides; our intestines hold 1014 microbial cells, 
outnumbering human cells by a factor of ten (Bäckhed et al. 2005; Savage, 1977). The 
main bacterial phyla detected in the GI tract using molecular methods are Firmicutes, 
Bacteroidetes, Actinobacteria, Fusobacteria, Verrucomicrobia and Proteobacteria 
(Rajilić-Stojanović, 2007). The intestinal microbiota is relatively stable through time 
and individual-specifi c (Ley et al. 2006b; Matsuki et al. 2004; Zoetendal et al. 1998). 
Moreover, alterations in the composition of the intestinal microbiota have been associated 
with an impaired state of health (Dicksved et al. 2008; Frank et al. 2007; Ley et al. 
2006b; Malinen et al. 2005; Manichanh et al. 2006; Rajilić-Stojanović, 2007; Sokol et 
al. 2008). 
Irritable bowel syndrome (IBS) is a functional bowel disorder commonly 
encountered world-wide (Longstreth et al. 2006). In Finland, the prevalence of IBS 
patients was 5.1% in 2001 (Hillilä & Färkkilä, 2004). The main symptoms of IBS are 
abdominal pain or discomfort, irregular bowel movements and constipation or diarrhoea. 
The syndrome is long-lasting in nature and IBS patients’ well-being may be signifi cantly 
affected, resulting in substantial costs to society in the form of health care visits and 
work absenteeism (Talley, 2008). Several possibly interacting causes of IBS have 
been investigated including intestinal bacteria involvement, low-grade infl ammation, 
altered motility and sensitivity in the GI tract and psychological stress and disturbances 
(Drossman et al. 2002).
Molecular methods are often applied in studies on intestinal microbiota to target 
uncultivable bacteria in addition to the cultivable bacteria (Carey et al. 2007; Zoetendal 
et al. 2008). In this study, methods based on the guanine and cytosine percentages of 
microbial genomes and 16S ribosomal ribonucleic acid (rRNA) gene sequence have 
been applied. We aimed to design assays for analysing alterations in the intestinal 
microbiota of IBS patients compared with healthy controls and to apply these assays on 
actual samples.
1.1 Intestinal microbiota 
1.1.1 Composition of the adult intestinal microbiota
From a microbial point of view, a tremendous variety of physiologically connected 
environments exists in the human GI tract. In the mouth, multiple distinct microbial 
communities consisting predominantly of Firmicutes, Bacteroidetes, Proteobacteria, 
Actinobacteria, Fusobacteria, Spirochaetes, and a candidate division TM7 are found in 
the saliva and plaque (Keijser et al. 2008). 
The stomach (Figure 1), on the other hand, is believed to be comparatively resistant 
to microbial colonization due to acidity and digestive enzymes (Tannock, 2007), with the 
exception of Helicobacter pylori and possibly lactobacilli (Marshall & Warren, 1984; 
Ryan et al. 2008). Nevertheless, a diverse array of microbes, distinct from that of the 
upper parts of the GI tract, has been detected in the stomach with a culture-independent 
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approach, implying that the gastric microbiota has thus far been underestimated (Bik et 
al. 2006). 
In the small intestine, the bacterial load and diversity rise from 104 to 108 cells per 
millilitre of intestinal content towards the distal ileum (Figure 1). Bacillus, Lactobacillus 
and Streptococcus species together with Proteobacteria predominate in the lumen of the 
small intestine, with the abundance of clostridia increasing in the ileum (Booijink et al. 
2007). Reaching the colon, the transit slows down and the bacterial density rises from 
108 in the caecum and ascending colon to an average of 1011 to 1012 cells of bacteria per 
gram in faeces and the proportion of obligate anaerobic bacteria increases (Figure 1). 
The phyla Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria, Fusobacteria and 
Verrucomicrobia are present in the colon (Andersson et al. 2008; Eckburg et al. 2005; 
Gill et al. 2006; Hayashi et al. 2002a; Hayashi et al. 2002b; Kurokawa et al. 2007; 
Suau et al. 1999; Wang et al. 2005). In the small and large intestines, the mucosal and 
lumenal microbiotas are distinct from each other (Booijink et al. 2007; Zoetendal et al. 
2002). The main phyla detected in the human GI tract with 16S rRNA-based studies are 
presented in Table 1.
Figure 1. Characteristics of the human gastrointestinal microbiota. The average density of 
microbial cells, pH, lengths (Booijink et al. 2007) and microbial contents detected with molecular 
methods from the stomach (Bik et al. 2006), small intestine (Booijink et al. 2007) and large 
intestine (Zoetendal et al. 2008). Image by Erja Malinen.
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1.1.2 Development of the intestinal microbiota
The fi rst contact of a newborn with microbes occurs at birth through exposure to bacteria 
originating from the birth canal, the maternal faecal microbiota and the environment 
(Edwards & Parrett, 2002). The uniqueness of the infant intestinal microbiota is evident, 
as from the 136 clusters of orthologous groups enriched in infant faecal samples in a 
metagenomic analysis, 78 were characteristic to infants, as opposed to children and adults 
(Kurokawa et al. 2007). At the time of weaning, the GI microbiota starts to diversify, 
eventually resembling that of an adult (Edwards & Parrett, 2002).
The GI tract of breast-fed infants has been found to be mainly colonized by 
bifi dobacteria, lactobacilli and streptococci, whereas formula-fed infants harbour 
bifi dobacteria, Bacteroidetes, staphylococci, clostridia, Escherichia coli and lactobacilli 
(Harmsen et al. 2000; Penders et al. 2006). Contrary to the above-mentioned fi ndings, 
bifi dobacteria formed only a minor constituent of the GI microbiota of 14 full-term 
babies in the microarray study by Palmer et al. (2007). This could at least partially have 
been due to the lack of mechanical bacterial cell breakage during deoxyribonucleic acid 
(DNA) extraction and the high guanine plus cytosine (G+C) content of bifi dobacteria 
causing a bias in polymerase chain reaction (Salonen et al. 2009).
Table 1. Main phyla found in the human gut in 16S rRNA gene sequencing-based studies (Rajilić-
Stojanović, 2007). The abundance is given as the average detected number of bacterial cells per 
gram of intestinal content of the human gut. The number of phylotypes refers to the number of 
phylotypes detected in human gastrointestinal microbiota with culture-dependent and –independent 
studies during 1998-2006. Families or clusters with more than 10 detected phylotypes are 
presented, except for Verrucomicrobia, which is included due to its high abundance.
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1.1.3 Functions of the intestinal microbiota
The GI microbiota has a mutualistic relationship with its host and is involved in energy 
harvest from nutrients and mucus, synthesis of vitamins, metabolism of xenobiotics, 
renewal and differentiation of GI epithelial cells, formation of a barrier against pathogens 
and development and function of the immune system (Guarner, 2006; Ley et al. 2006a; 
Turnbaugh et al. 2007).
The principal products of microbial carbohydrate metabolism in the human GI tract 
are short-chain fatty acids (SCFAs), which can be absorbed by the human host. The 
SCFAs produced throughout the GI tract are mainly acetate, butyrate and propionate, but 
in the colon acetate predominates (Cummings et al. 1987). The colonic mucosa prefers 
butyrate over other SCFAs as an energy source, and butyrate has been shown to have 
a positive effect on health (Pryde et al. 2002). The most abundant intestinal butyrate-
producing bacteria are Firmicutes from Clostridial clusters XIVa and IV (Clostridium, 
Eubacterium, Fusobacterium) (Pryde et al. 2002). Starch fermentation by starch-
degrading bacteria results in comparatively high amounts of butyrate (Chassard et al. 
2008). Starch-degrading bacteria, including Ruminococcus bromii (Clostridium cluster 
IV), Eubacterium rectale (Clostridium cluster XIVa) and bifi dobacteria (Leitch et al. 
2007), comprise 10.1% of culturable bacteria in faecal samples (Chassard et al. 2008).
Mucins are produced by the host and form a protective lubricating layer on the 
intestinal epithelium (Derrien, 2007) that is speculated to have a role in intestinal 
health (Lutgendorff et al. 2008). Mucins form an energy source for 5.1% of culturable 
intestinal bacteria (Chassard et al. 2008) including certain Clostridial cluster XIVa 
isolates (Clostridium indolis 96% and Ruminococcus sp.), Bacteroides vulgatus, several 
Bifi dobacteria (Bifi dobacterium adolescentis, Bifi dobacterium breve and Bifi dobacterium 
longum) and Akkermansia muciniphila (Derrien et al. 2004; Leitch et al. 2007).
1.1.4 Intestinal microbiota and health
An increasing number of studies have provided compelling evidence that the GI microbiota 
plays a key role in human health. The intestinal microbiota reacts to antibiotic therapies 
(Mellon et al. 2000), probiotics (Kajander et al. 2008; Surawicz, 2003), dietary strategies 
(Hayashi et al. 2002a) and obesity (Ley et al. 2006b; Turnbaugh et al. 2006), and it may 
have a role in the development of allergies (Kirjavainen et al. 2001; Watanabe et al. 
2003). The normal microbiota may also contribute to the development of chronic states 
of recurring infl ammation of the intestinal tract, such as infl ammatory bowel disease 
(IBD), or functional intestinal disorders, such as IBS. Alterations in the composition of 
faecal and mucosal microbiotas (Tables 2 and 3, respectively) have been detected in both 
IBD, including Crohn’s disease and ulcerative colitis, and IBS.
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Table 2. Alterations of gut microbiota associated with IBS and IBD detected in faecal samples.
Alteration in GI microbiota No. of subjects Method used Reference


















(Mättö et al. 2005) 
Higher temporal instability
IBS-C had less Clostridium coccoides-





(Maukonen et al. 
2006) 
More C. coccoides and Bifi dobacterium 
catenulatum group bacteria
IBS subtype-specifi c differences in 




Real-time PCR (Malinen et al. 
2005) 
Distinctive clustering of phylotypes













(Seksik et al. 
2003)






(Manichanh et al. 
2006) 
Lower temporal stability of dominant 
bacteria in CD




DGGE (Scanlan et al. 
2006) 
Higher proportion of bacteria detected in 
control subjects with 6 probes
Clostridium coccoides group reduced in UC
Clostridium leptum group reduced in CD





FISH (Sokol et al. 2006) 
Lower bacterial diversity in CD
Healthy twins more similar than CD twins
Alterations in abundances of Bacteroides 
species
10 CD monozygotic 
twin pairs




(Dicksved et al. 
2008) 
CD, Crohn’s disease; DGGE, denaturing gradient gel electrophoresis; FISH, fl uorescent in situ 
hybridization; %G+C, percent guanine plus cytosine profi ling; HITChip, Human Intestinal Tract Chip; 
IBS, irritable bowel syndrome; IC, infectious colitis; Real-time PCR, real-time polymerase chain reaction; 
TGGE, temperature gradient gel electrophoresis; TRAC, transcript analysis with aid of affi nity capture; 
TRFLP, terminal restriction fragment length polymorphism; UC, ulcerative colitis
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Table 3. Alterations of gut microbiota associated with IBS and IBD detected using mucosal 
biopsy samples.
Alteration in GI microbiota No. of subjects Method used Reference
Reduction in diversity due to loss of 
Bacteroides, 







(Ott et al. 2004) 
Bacteria more abundant in IBD patients
Bacteroides dominant in IBD
Eubacterium rectale-Clostridium coccoides 
group dominant in IBS 
50 CD
60 non CD 
controls
FISH (Swidsinski et al. 
2005) 
Distinctive clustering of DGGE fi ngerprints
Greater variability among CD patients’ 
microbiota
Clostridium cluster XIVa more prevalent in 
CD
Ruminococcus torques-like phylotype more 
prevalent in CD
Enterobacteriaceae more prevalent in CD
Faecalibacterium prausnitzii-like phylotype 









et al. 2006) 
Lower abundance of Bacteroidetes and 
higher abundance of Firmicutes associated 
with infl amed tissue of IBD patients
Species richness highest in non-infl amed 






(Sepehri et al. 
2007) 
Faecalibacterium prausnitzii associated with 
lower risk of postoperative relapse in CD
Faecalibacterium prausnitzii reduced severity 






(Sokol et al. 
2008)
Clone libraries of CD, UC and non-IBD differ 
signifi cantly









(Frank et al. 
2007) 
Low abundance of F. prausnitzii and high 
abundance of Escherichia coli associated 
with ileal CD
6 discordant 
monoz. CD twin 
pairs
4 concordant 






(Willing et al. 
2008)
ARISA, automated ribosomal intergenic spacer analysis; CD, Crohn’s disease; DGGE, denaturing gradient 
gel electrophoresis; FISH, fl uorescence in situ hybridization; IBD, infl ammatory bowel disease; IBS, 
irritable bowel syndrome; IC, ischemic colitis; rDNA, ribosomal deoxyribonucleic acid; Real-time PCR, 
real-time polymerase chain reaction; SSCP, single-strand conformation polymorphism; TRFLP, terminal 
restriction fragment length polymorphism; UC, ulcerative colitis.
Introduction
15
1.2 Irritable bowel syndrome (IBS)
1.2.1 Symptoms
The word “syndrome” derives from the Greek word “sundrom”, literally meaning “run 
together” or “meeting”. In medicine, the term refers to several features, signs, symptoms, 
phenomena or characteristics often occurring simultaneously. IBS is a functional 
disorder of the GI tract. The worldwide prevalence of IBS has been estimated to be in 
the range of 10-20% among adults and adolescents, depending on the diagnostic criteria 
applied (Longstreth et al. 2006). In Finland, the prevalence of IBS patients fulfi lling 
Rome II Criteria was 5.1% of the general population in 2001 (Hillilä & Färkkilä, 2004). 
Abdominal pain or discomfort, irregular bowel movements and constipation or diarrhoea 
are common symptoms of IBS (Longstreth et al. 2006).
Symptoms outside the GI tract, such as fatigue, anxiety and depression, are also often 
encountered (Tillisch & Chang, 2005). At its worst, IBS can cause signifi cant effects on 
patients’ well-being, but it is not known to predispose to any severe illnesses. Patients 
can be grouped into three subtypes according to bowel habits: diarrhoea-predominant 
(IBS-D), constipation-predominant (IBS-C) or mixed-subtype (IBS-M) (Drossman, 
2006; Longstreth et al. 2006). However, the symptom subtype of each patient may vary 
over time (Longstreth et al. 2006).
1.2.2 Diagnostic criteria for IBS
Diagnostic symptom criteria for IBS aid in distinguishing the syndrome from organic 
causes and in differentiating it from other functional bowel disorders (Longstreth 
et al. 2006). Therefore, internationally agreed criteria are used in diagnosing IBS, in 
epidemiological surveys, in research and in therapeutic trials. The fi rst Rome guidelines 
for IBS (also known as the Rome-2 IBS Criteria) presented in Rome in 1988 (Thompson 
et al. 1989) were based on the Manning (Manning et al. 1978) and Kruis (Kruis et 
al. 1984) criteria for IBS and on two epidemiological studies (Drossman et al. 1982; 
Whitehead et al. 1982). They were the result of the international collective effort of 
experts in gastroenterology chaired by W. Grant Thompson (Thompson, 2006).
Table 5. Rome II diagnostic criteria for irritable bovel syndrome
Rome II criteria (Thompson et al. 1999) 
At least 6 months of recurrent symptoms of abdominal discomfort or pain
 relieved by defecation
 and/or associated with a change in stool frequency
 and/or associated with a change in stool consistency
And two or more of the following:
 altered stool frequency
 altered stool form
 altered stool passage
 passage of mucus
 bloating or feeling of abdominal distension
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Thus far, Rome criteria I, II and III have been published (Longstreth et al. 2006; 
Thompson et al. 1992; Thompson et al. 1999). Rome II criteria were applied in this 
study (Table 4). In the more recent Rome III criteria, the temporal demands became 
less rigorous and the requirement for relief of abdominal symptoms with defecation 
was changed to improvement of symptoms. The diagnostic criteria for IBS are under 
constant development by specialists according to accumulating knowledge (Thompson, 
2006).
1.2.3 Aetiology of IBS
Multiple theories have been proposed to explain the aetiology of IBS. These include 
physiological features, such as altered GI motility and visceral hypersensitivity, 
psychological stress and disturbances, low-grade infl ammation, small intestinal bacterial 
overgrowth, and bacterial gastroenteritis (Drossman et al. 2002). Infl ammation has 
been suggested to have a primary role in IBS aetiology; microbial infection, bacterial 
microbiota alteration (see following section) and abnormal response to a normal 
microbiota could cause low-grade infl ammation, which could affect motility and visceral 
sensitivity (Quigley, 2006). Furthermore, environmental stress can alter GI motility and 
visceral sensitivity through the brain-gut axis (Quigley, 2006).
In a large cohort study (over 500 000 patients), gastroenteritis was concluded to 
increase the risk of developing IBS by a factor of ten (Rodriguez & Ruigomez, 1999). 
Post-infectious IBS (PI-IBS) has been reported after Campylobacter, Shigella and 
Salmonella infections (Ji et al. 2005; Mearin et al. 2005; Spiller et al. 2000), but appears 
to be a non-specifi c response (Spiller, 2007). Typically PI-IBS is characterized by loose 
stools, less depression and anxiety and increased enterochromaffi n cells in mucosal 
biopsies compared with non-PI-IBS (Dunlop et al. 2003; Neal et al. 2002). Since the 
initial gastroenteritis triggering PI-IBS is a coincidental event, and among PI-IBS 
patients the symptoms are relatively homogeneous and psychological abnormalities are 
less common than in other IBS patients, PI-IBS presents a clearer model for studying the 
possible mechanisms underlying IBS (Spiller, 2007).
Elevated faecal serine protease activity has been associated with IBS-D (Roka 
et al. 2007). The faecal supernatants from IBS-D patients caused increased colonic 
paracellular permeability when administered to the mucosal side of a mouse colon strip 
and increased visceral hypersensitivity in mice (Gecse et al. 2008). Gecse et al. (2008) 
also showed that the effect on mucosal permeability is mediated by serine protease 
through protease-activated receptor two (PAR-2). Pre-incubation with serine protease 
inhibitors decreased the effect of the faecal supernatant from the IBS-D patients on the 
colonic paracellular permeability of mouse colon strips. Furthermore, the use of colonic 
strips derived from PAR-2-defi cient mice completely removed the increase in colonic 
paracellular permeability. The elevated serine protease activity in IBS-D patients was 
suggested to be of microbial origin (Gecse et al. 2008).
Additionally, antibodies against certain bacterial fl agellin have been detected in IBS 
patients, particularly in PI-IBS patients, with a higher frequency than in healthy controls 
(Schoepfer et al. 2008). Furthermore, the basal and E. coli lipopolysaccharide induced 
release of pro-infl ammatory cytokines from peripheral blood mononuclear cells has 
been shown to be elevated in IBS-D patients compared to healthy controls (Liebregts 
Introduction
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et al. 2007). Low-grade mucosal infl ammation (Barbara et al. 2007; Chadwick et al. 
2002; Dunlop et al. 2003; Ohman et al. 2005) and stable alterations in mucosal gene 
expression (Aerssens et al. 2008) of IBS patients of all symptom subtypes have also been 
detected. These fi ndings, together with the IBS-associated GI microbiota alterations, 
imply that bacteria, host-microbe interactions and infl ammation may well play a role in 
IBS aetiology.
1.2.3.1 Intestinal microbiota
IBS-related alterations in the GI microbiota have been investigated by conventional 
culture-based methods (Balsari et al. 1982; Mättö et al. 2005; Si et al. 2004) and molecular 
methods based on the 16S rRNA gene sequence (Malinen et al. 2005; Mättö et al. 2005; 
Maukonen et al. 2006; Rajilić-Stojanović, 2007; Swidsinski et al. 2005). Using culture-
based techniques, the GI microbiota of IBS patients was characterized as having less 
coliforms, lactobacilli and bifi dobacteria in a study with 20 IBS patients and 20 controls 
(Balsari et al. 1982). Likewise, in a later study (Si et al. 2004), with 25 IBS patients 
fulfi lling the Rome II criteria and 25 controls, lower levels of bifi dobacteria were detected 
in IBS patients, but the level of bacteria belonging to the family Enterobacteriaceae was 
higher in IBS patients. Contrary to Balsari et al. (1982), Mättö et al. (2005) detected 
more coliforms in IBS subjects’ samples using culture-based methods.
Greater temporal instability of the intestinal microbiota of IBS patients compared 
with that of healthy controls has been detected with RNA-based denaturing gradient gel 
electrophoresis (Maukonen et al. 2006). The same authors also quantifi ed the clostridial 
groups from the samples with a novel method, transcript analysis with aid of affi nity 
capture (TRAC). With TRAC, IBS-C patients were found to have less Clostridium 
coccoides – E. rectale group bacteria than control subjects.
The sample set studied by Mättö et al. (2005) and Maukonen et al. (2006) was 
further studied using 20 real-time PCR assays covering approximately 300 bacterial 
species (27 IBS patients and 22 controls gave faecal samples at the fi rst time-point; 21 
IBS patients and 15 controls gave faecal samples at three time-points at three-month 
intervals) (Malinen et al. 2005). The fi rst time-point was analysed with IBS subjects 
divided into symptom subgroups; IBS-D, IBS-C and IBS-M. Statistically signifi cant 
differences were observed with real-time PCR assays targeting Lactobacillus spp. (less 
abundant in IBS-D than in IBS-C), Veillonella spp. (less abundant in controls than in 
IBS-C) and Bifi dobacterium spp. (less abundant in IBS-D than in all other groups). 
The C. coccoides and Bifi dobacterium catenulatum group assays detected more target 
bacteria in controls than in IBS patients when the results from the three different time-
points were averaged and the IBS subjects analysed as a single group.
Fluorescent in situ hybridization (FISH) applied on mucosal samples of patients 
with IBD, IBS or no GI symptoms revealed that mucosal bacteria were more abundant 
in IBS patients than in healthy controls, although the difference was less evident than 
with the IBD patients (Swidsinski et al. 2005). The proportional amounts of the different 
bacterial groups targeted in the FISH analysis (Bacteroides-Prevotella, B. fragilis, E. 
rectale-C. coccoides, Faecalibacterium prausnitzii and Enterococcus faecalis) were 
similar between IBS patients and controls. 
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The fi rst analysis concerning IBS-associated GI microbiota applying a microarray 
(The Human Intestinal Tract Chip, HITChip) was published in June 2007 in the PhD 
thesis of Rajilić-Stojanović (Rajilić-Stojanović, 2007). The HITChip is a 16S rRNA 
gene-based phylogenetic microarray specifi cally designed to target the human intestinal 
microbiota. The HITChip is unable to quantify phylotypes directly, but relative changes 
in hybridization signals can be detected between 0.1% and 3% subpopulations in an 
artifi cial mixture of 30 phylotypes (Rajilić-Stojanović, 2007). The HITChip study on 
IBS encompassed 20 IBS patients subgrouped according to symptom subtype and 20 
healthy controls. With a hierarchical cluster analysis, the phylogenetic fi ngerprints of 
the faecal microbiota of IBS patients and controls grouped into two distinctive groups, 
with one dominated by IBS patients’ samples (14 IBS patients and 4 controls) and the 
other by healthy controls’ samples (16 controls and 6 IBS patients). The clustering did 
not correlate with the IBS symptom subtype. Stronger variation in the composition of 
the microbiota was seen among the IBS patients’ profi les.
Within the phylotypes targeted by the HITChip, the IBS-C group of IBS patients 
had lower levels of Bacteroides species (Bacteroides ovatus, Bacteroides uniformis, 
Bacteroides vulgatus) and Clostridium stercorarium-like bacteria and higher levels of 
Bacillus spp.; the IBS-D patients were characterized by higher levels of Aneuribacillus 
spp., Streptococcus mitis and Streptococcus intermedius-like bacterial phylotypes from 
the order Bacilli. Various IBS-subgroup dependent differences were detected within 
Clostridium cluster XIVa (C. coccoides group). For instance, Roseburia intestinalis 
was more abundant in IBS-D and Ruminococcus gnavus in alternating-type IBS than in 
healthy controls. Several phylotypes within the Clostridium cluster IV (the Clostridium 
leptum –group) were more prominent in IBS-C than in IBS-D. (Rajilić-Stojanović, 
2007.)
Taken together, these studies show that alterations in the GI microbiota of IBS 
patients compared with the microbiota of healthy controls exist and warrant further 
research. In particular, the application of sequencing-based approaches would yield 
potentially valuable IBS-associated sequence data.
1.2.3.2 Intestinal metabolites
Reduced amounts of total SCFAs due to lower levels of acetate and propionate have 
been measured in association with IBS-D, while an elevated concentration of n-butyrate 
seemed to be characteristic of IBS-D (Treem et al. 1996). Colonic gas production (H2 
and CH4) has been shown to be greater in patients with IBS (Rome II criteria) compared 
with controls using a standardized diet, which might be associated with alterations in the 
activity of hydrogen-consuming bacteria (King et al. 1998). An exclusion diet, mainly 
devoid of dairy products and cereals other than rice, reduced IBS symptoms and lowered 
the maximum gas excretion (King et al. 1998). Furthermore, IBS-C has been associated 
with methane excretion using lactulose breath test (Pimentel et al. 2003).
1.2.4 Probiotics as promising remedies for IBS symptoms
In 1989, Fuller defi ned probiotics as “live microbial food supplements which benefi cially 
affect the host by improving the intestinal microbial balance” (Fuller, 1989). Probiotics 
have been shown to reduce IBS symptoms in several studies (for review, see Wilhelm 
Introduction
19
et al. 2008 and Spiller, 2008). Relief of bloating (Kim et al. 2003), fl atulence (Kim et 
al. 2005), abdominal distension (Bausserman & Michail, 2005), abdominal pain and 
fl atulence (Nobaek et al. 2000) and overall symptoms (Kajander et al. 2005; Kajander et 
al. 2008; O’Mahony et al. 2005) have been observed in randomized placebo-controlled 
intervention studies. As pointed out by Kajander in her thesis, any treatment applied as 
IBS therapy should be safe since the syndrome is benign (Kajander, 2008).
The intestinal microbiota has been evaluated in three probiotic interventions on 
IBS patients. Lactobacillus plantarum (DSM 9843) administered in a rose-hip drink 
decreased abdominal pain and fl atulence (Nobaek et al. 2000). The abundances of 
Enterobacteriacea, sulphate-reducing bacteria or Enterococci were not altered in the 
probiotic group, but the probiotic strain was detected in faecal and rectal mucosal 
samples (Nobaek et al. 2000). The intestinal microbiota of IBS patients receiving a 
multispecies probiotic consisting of Lactobacillus rhamnosus GG, L. rhamnosus Lc705, 
Propionibacterium freudenreichii ssp. shermanii JS and Bifi dobacterium breve Bb99 
or a placebo capsule was analysed with a set of 20 real-time PCR assays targeting 
approximately 300 intestinal bacteria, but no effects were detected in the indigenous GI 
microbiota of the treatment group (Kajander et al. 2007). In a more recent intervention 
study, a similar multispecies probiotic supplement consisting of L. rhamnosus GG, L. 
rhamnosus Lc705, P. freudenreichii ssp. shermanii JS and Bifi dobacterium animalis 
ssp. lactis Bp12 was discovered to be effective in relieving IBS symptoms, especially 
abdominal pain and distension, and stabilizing the intestinal microbiota (Kajander et al. 
2008).
1.3 Nucleic acid-based methods for analysing the GI microbiota
Molecular biology methods have become popular in microbial ecology studies since 
they do not require cultivation of microbes. The ribosomal RNA gene is especially useful 
due to the extensive accumulation of 16S ribosomal deoxyribonucleic acid (rDNA) 
sequences in public databases. The human GI microbiota can be studied with a vast 
array of molecular methods (Figure 2). The methods applied in this study are discussed 
in more detail in sections 1.3.1 to 1.3.3.
Sequencing is a prerequisite for other DNA- or RNA-based molecular methods. 
Cloning and sequencing of 16S rRNA gene libraries is biased as to quantity of phylotypes, 
but novel species can be detected and their 16S rRNA sequences utilized further with 
other molecular techniques (Zoetendal et al. 2008). Real-time PCR and FISH give 
quantitative results, but the target sequence has to be known beforehand. Microarray 
techniques are semi-quantitative and enable a vast diversity of phylotypes to be analysed 
in a single assay. A leap further has been taken with metagenomics, which analyses the 
total microbial DNA within the ecosystem of interest. Genes of various functions can be 
annotated from the metagenomic data in a semi-quantitative manner. Furthermore, the 
16S rRNA gene sequence data in a metagenomic library can be used for phylogenetic 
analyses.
By the beginning of the year 2006, almost 900 rRNA gene based phylotypes 
originating from the human GI tract were available in public sequence databases 
(Rajilić-Stojanović et al. 2007). The richness estimates extend to 300 phylotypes within 
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an individual’s colon (Eckburg et al. 2005), with distinct disparity between individuals, 
indicating subject-specifi c variation (Eckburg et al. 2005; Ley et al. 2006b; Zoetendal 
et al. 1998). The main phyla found in 16S rRNA gene sequencing-based studies have 
been Firmicutes, Bacteroidetes, Proteobacteria, Actinobacteria, Fusobacteria and 
Verrucomicrobia (Bonnet et al. 2002; Eckburg et al. 2005; Hayashi et al. 2002a; Hayashi 
et al. 2002b; Suau et al. 1999; Wang et al. 2005) (Table 1). In principle, all bacteria 
present in a sample can be analysed using culture-independent molecular methods. 
Nevertheless, the result is affected by sampling protocol, sample handling, nucleotide 
extraction method, selection of primers and probes and the analysis method applied.
1.3.1 Real-time polymerase chain reaction (PCR)
Quantitative real-time PCR was developed in 1993 by Higuchi and colleagues. In the 
fi rst application, the fl uorescence of double-stranded DNA (dsDNA)-bound ethidium 
bromide was used to detect the accumulation of amplifi ed DNA in the reaction. The 
original amount of target DNA in the sample can be deduced from the number of PCR 
cycles required to reach detectable fl uorescence. Higuchi and his team were able to detect 
single-stranded Human Immunodefi ciency Virus template DNA with a linear range 
Figure 2. Nucleic acid-based methods for studying the microbiota of the GI tract. Culturing is 
necessary for phenotypic characterization of bacteria, whereas molecular methods can be applied 
to study the genotype of bacteria (sequencing, metagenomics) and the diversity (sequencing, 
metagenomics, DGGE/TGGE, microarray) and spatial distribution (FISH) of the microbiota. 
FISH, real-time PCR and dot-blot hybridization are quantitative methods, and microarray is a 
semi-quantitative method. Percent G+C profi ling can be used to refl ect the bacterial community 
structure. Denaturing gradient gel electrophoresis, DGGE; guanine plus cytosine, G+C; 
fl uorescent in situ hybridization, FISH; real-time polymerase chain reaction, real-time PCR; 
temperature gradient gel electrophoresis, TGGE.
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from 103 to 108 template copies (Higuchi et al. 1993). Real-time PCR has subsequently 
become a popular method in molecular biology (over 30 000 publications applying real-
time PCR were available in PubMed in October 2008). An array of possible detection 
strategies exists that involve dsDNA intercalating dyes and sequence-specifi c labelled 
oligonucleotide probes, making multiplex real-time PCR an option (for review see Carey 
et al. 2007, Kubista et al. 2006 and Mackay, 2004).
In human GI research, real-time PCR has been used for detecting pathogens (Amar 
et al. 2005; Peterson et al. 2007; van Doornum et al. 2007), for quantifying specifi c 
microbial groups within the GI tract (Chen et al. 2007; Fite et al. 2004; Gueimonde et al. 
2007; Stewart et al. 2006), for the microbiota as a whole (Bartosch et al. 2004; Hopkins 
et al. 2005; Matsuki et al. 2002; Penders et al. 2006) and in probiotic (Bartosch et al. 
2005; Kajander et al. 2007) and health (Malinen et al. 2005; Willing et al. 2008) related 
studies.
1.3.2 Percent guanine plus cytosine (G+C) profi ling
Fractionation of bacterial genomic DNA from population samples according to its genomic 
G+C content was developed by Holben and Harris (1995). The method was based on 
DNA-binding bisbenzimidazole, which preferentially binds to adenine and thymidine 
and changes the buoyant density of DNA proportionally to the amount of dye bound. 
Holben and Harris (1995) showed that the genomic DNA of Clostridium perfringens 
(27% G+C content), E. coli (50% G+C content) and Micrococcus lysodeicticus (72% 
G+C content) could be separated in an equilibrium density gradient caesium-chloride-
bisbenzimidazole centrifugation, that the relationship between the buoyant density 
of DNA and the G+C content was linear and that the method was useful for bacterial 
community analysis of bacterial community samples.
The %G+C profiling has been shown to enrich the detectable diversity of an 
environmental microbial genomic DNA sample, and therefore, the method is also 
valuable as a preprocessing treatment (Holben et al. 2004; Nusslein & Tiedje, 1998). 
The G+C profi ling method has been applied to characterization of bacterial communities 
in soil (Holben & Harris, 1995; Nusslein & Tiedje, 1998), and to monitoring diet-related 
alterations in the GI microbiota of broiler chickens (Apajalahti et al. 2001), the effects 
of inulin on the mouse caecum microbiota (Apajalahti et al. 2002), the effects of lactose 
on a colon simulator (Mäkivuokko et al. 2006), and the bifi dobacterial (Apajalahti et al. 
2003) and IBD-associated (Dicksved et al. 2008) human GI microbiota.
1.3.3 Sequencing of 16S rRNA gene
The ca. 1500 base pair (bp) long 16S rRNA gene found in all prokaryotes can be used 
for estimating microbial diversity (Lozupone & Knight, 2008; Rossello-Mora & Amann, 
2001; Woese, 1987). In the 16S rRNA gene primary structure, variable and highly 
conserved sequence regions alternate, which enable sequencing of 16S rRNA genes of 
unknown bacteria using universal primers annealing to the conserved parts of the gene. 
To date, close to one million (992 735 in November 2008) 16S rRNA entries have been 
submitted to public sequence databanks, constituting a large reference sequence data 
set. Over 15 000 of these sequences originate from human intestinal samples (Rajilić-
Stojanović, 2007). One advantage of sequencing in intestinal microbiota studies is the 
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possibility of detecting unculturable bacteria and novel species.
The Sanger sequencing method used in this study applies dideoxy analogues of 
deoxynucleoside triphosphates, which terminate polymerization at a known base (Sanger 
et al. 1977). Later, the invention of pyrosequencing (Margulies et al. 2005) and the use 
of barcoded primers (Binladen et al. 2007) have made sequencing cost-effective and 
high-throughput. Andersson et al. (Andersson et al. 2008) demonstrated the applicability 
of barcoded 16S rDNA pyrosequencing for human intestinal microbiota. The 16S rDNA 
sequences can be used to estimate species richness and diversity in a microbial community 
(Schloss & Handelsman, 2005) and to compare different communities (Lozupone & 
Knight, 2008; Schloss et al. 2004; Schloss & Handelsman, 2006).
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2. Aims of the study
i. To test the applicability of real-time PCR for the quantifi cation of bacteria from 
faecal samples (I) 
ii. To design real-time PCR assays for the quantifi cation of an extensive set of 
indigenous and selected pathogenic bacterial species (I and II) 
iii. To compare the overall faecal microbiota of IBS patients and that of healthy 
volunteers with the whole genome and with 16S rDNA-based approaches 
(Figure 3; III) 
iv. To determine and quantify specifi c bacterial 16S rRNA gene-based phylotypes 
constituting differences between the faecal microbiota of IBS patients and that of 
healthy volunteers (Figure 3; III and IV) 
Figure 3. Study outline comparing the faecal microbiota of IBS patients with that of healthy 
volunteers. The %G+C profi ling and analysis of partial 16S rDNA sequence libraries compare the 
faecal microbiotas as a whole, whereas the real-time PCR analyses on subject-specifi c samples are 
used to quantify and compare the abundances of selected phylotypes. DNA, deoxyribonucleic acid; 
G+C, guanine plus cytosine; IBS, irritable bowel syndrome; IBS-C, constipation-predominant 
IBS; IBS-D, diarrhoea-predominant IBS; IBS-M, mixed-subtype IBS; real-time PCR, real-time 
polymerase chain reaction.
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3. Materials and methods
3.1 Study subjects (II-IV)
The recruiting of all IBS patients was done by experienced physicians under the 
coordination of the dairy company Valio Ltd. The IBS patients analysed in this study 
fulfi lled the Rome II criteria (Thompson et al. 1999), with the exception of three subjects 
who had slightly less than 12 weeks of abdominal pain during the preceding year (Table 
5). The patients had undergone clinical investigation and endoscopy or barium enema of 
the GI tract within the year previous to the study.
The IBS patients had participated in a clinical probiotic intervention study (Kajander et 
al. 2007) and received daily a placebo capsule consisting of microcrystalline cellulose, 
magnesium stearate and gelatine as encapsulating material. Three and 24 IBS patients 
were analysed at one time-point (0 months) in Studies II and III, respectively. All three 
time-points (0, 3 and 6 months) were analysed for 20 IBS patients in Study IV.
The recruitment of a control group devoid of regular GI symptoms was coordinated 
by VTT Biotechnology (Espoo, Finland, Table 5). The control group was age- and 
gender-matched to the placebo IBS group (Mättö et al. 2005). The control group was 
also sampled at three time-points (0, 3 and 6 months). Altogether 15 control subjects 
completed the six-month study and were included in Study IV.
All subjects gave their written informed consent and were told that they could 
withdraw from the study at any time. The Human Ethics Committee at The Joint 
Authority for the Hospital District of Helsinki and Uusimaa (IBS patients) and the Ethics 
Committee of VTT (controls) approved the study protocol.
The above-mentioned samples have been analysed in multiple studies under 
the Finnish Funding Agency for Technology and Innovation (TEKES) project (no. 
40039/03) (Malinen et al. 2005; Mättö et al. 2005; Maukonen et al. 2006) and by Valio 
Ltd. (Kajander et al. 2005; Kajander et al. 2007).
3.2 Sample handling and DNA extraction (I-V)
The faecal samples were obtained at three time-points three months apart. The subjects 
defecated in a plastic container made anaerobic with Anaerocult A mini (Merck, Darmstadt, 
Germany), whereafter the samples were immediately transported to VTT Biotechnology 
(Mättö et al. 2005). Under anaerobic conditions, the samples were homogenized by 
mixing with a wooden spatula and divided into subsamples. All samples were stored in 
-70°C prior to DNA extraction.
Extractions of DNA from bacterial cells and faecal samples were performed 
according to Apajalahti et al. (1998). Faecal bacteria were washed with repeated 
low-speed centrifugations after which the bacteria were pelleted with a high-speed 
centrifugation from the combined supernatants. The cells from the pelleted faecal 
bacteria (I-IV) and pure cultures of reference strains (Table 6; I-IV) were lysed with 
a combination of freeze-thaw cycles, lysozyme and vortexing with glass beads. The 
extraction method was evaluated by quantifi cation of E. coli subgroup bacteria from 
faecal samples spiked with a dilution series of E. coli DSM 6897 cultures (II) and with a 
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Table 5. Characteristics of IBS patients and controls.
Characteristic IBS patients Controls
Time-points (months) 0 0, 3 and 6 0 0, 3 and 6
No. of subjects 24 20 23 15
Age (years) : mean 
(range) 
47 (21-65) 47 (24-64) 45 (24-64) 47 (25-64)
Gender: Female/Male 19/5 14/6 16/7 10/5
Predominant bowel habit
 Diarrhoea: n 10 8 - -
 Constipation: n 8 8 - -
 Alternating: n 6 4 - -














All exclusion criteria of the irritable 
bowel syndrome patients
*Missing from Table 1 in Studies III and IV. IBS, irritable bowel syndrome.
QIAamp DNA stool mini kit (QIAgen, Hilden, Germany) according to the manufacturers 
protocol for isolating DNA from stool for pathogen detection.
3.3 Design of oligonucleotide primers and probes (I-IV)
The dot-blot hybridization probes, real-time PCR primers and TaqMan probes used 
in Studies I and II were designed on the basis of publicly available 16S rRNA gene 
sequences using ClustalW 1.83 (Thompson et al. 1994) for the alignment of sequences. 
Potential primer and probe sites were assessed either manually or using Primer3 online 
interface (Rozen & Skaletsky, 2000). The specifi city of the probes and primers was 
checked with FASTA3 (Pearson & Lipman, 1988) and the Probe Match and Hierarchy 
Browser applications of the Ribosomal Database Project II (RDP II, RDP release 8.1) 
(Cole et al. 2003).
The 16S rRNA gene libraries constructed from the faecal samples of different 
IBS symptom subtype patients and healthy volunteers (III) were compared using ARB 
(Ludwig et al. 2004) and ClustalW 1.83 (Thompson et al. 1994) alignments. Sequences 
that were phylogenetically close to each other and present in diverging numbers in 
different clone libraries were chosen as target sequences for design of real-time PCR 
assays in Studies III and IV. The primers were designed using the same tools as in Studies 
I and II. The assays were named according to the closest cultured bacterial species with 
the 16S rRNA gene sequence similarity percentages below 98% indicated.
3.4 Dot-blot hybridization (I) 
Dot-blot hybridizations are described in Study I. In brief, denatured DNA samples were 
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blotted on positively charged nylon membranes (Boehringer Mannheim, Mannheim, 
Germany), prehybridized with unspecifi c denatured DNA (Herring Sperm DNA, Sigma-
Aldrich, St. Louis, MO, USA) and hybridized with oligonucleotide probes (Table 7) 
labelled at the 5`-end with [-33P] adenosine triphosphate (GE Healthcare Bio-Sciences 
AB, Uppsala, Sweden). After washing the membranes in stringent washing temperatures, 
the dots were quantifi ed using Multi-Imager (Bio-Rad, Hercules, CA, USA).
3.5 Real-time PCR (I-IV)
For real-time PCR analyses, the iCycler iQ apparatus (Bio-Rad) associated with the 
ICYCLER OPTICAL SYSTEM INTERFACE software (version 2.3; Bio-Rad) was 
used in all four studies. For each assay, the optimal annealing temperature, MgCl2 
concentration and fl uorescence measurement temperature were assessed prior to analysis 
of samples (Table 7). To reduce costs, the Dynazyme II DNA polymerase (Finnzymes, 
Espoo, Finland) was used instead of hot-start polymerases with SYBR Green I chemistry 
in Studies II-IV. All samples were analysed in triplicate using 96-well optical-grade PCR 
plates together with standards ranging from 0.1 pg to 10 ng of genomic DNA (I and 
II) or 102 to 107 copies of 16S rRNA gene (III and IV). Genomic DNA of non-target 
GI bacteria (I and II) or the amplifi ed 16S rRNA gene from a phylogenetically closely 
related clone (III and IV) was used as a negative control.
Bacterial strains were used as positive and negative controls and standards in dot-
blot hybridizations and real-time PCR assays (Table 6). The media and growth conditions 
used are presented in the original articles. 
Table 2. Bacterial strains used in Studies I-IV.
Bacterial strain1) Study
Atopobium parvulum ATCC 33793 II
Bacteroides fragilis DSM 2151 I, II
Bifi dobacterium lactis DSM 10140 I
Bifi dobacterium longum DSM 20219 I-IV
Campylobacter jejuni Neqas 6037 II
Clostridium diffi cile ATCC9689 II
Clostridium perfringens ATCC 13124 II
Desulfovibrio desulfuricans ATCC 7757 II
Enterococcus faecalis DSM 20478 II
Escherichia coli DSM 6897 I, II
Faecalibacterium prausnitzii ATCC 27766 II
Fusobacterium nucleatum ATCC25586 II
Helicobacter pylori DSM 4867 II
Lactobacillus acidophilus ATCC 4356 I, II
Lactobacillus casei ATCC393 II
Ruminococcus productus DSM 2950 I, II
Veillonella parvula ATCC 10790 II
1)The Department of Microbiology at the National Public Health Institute (Helsinki, Finland) and the Department of 
Food and Environmental Hygiene at the University of Helsinki are kindly acknowledged for providing bacterial strains.
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3.5.1 Real-time PCR data analysis (I-IV)
Depending on the template used, the real-time PCR results were converted to the 
average estimate of bacterial genomes or 16S rRNA gene copies per 1 g of faeces (wet 
weight). When estimating the numbers of bacterial genomes in the faecal samples, 
average genome sizes for target bacteria were used and differences in the rRNA gene 
copy numbers were excluded. To calculate the proportional amounts of target bacteria, 
the quantity of eubacteria in the faecal samples were estimated with real-time PCR using 
universal 16S rDNA primers (Nadkarni et al. 2002).
For statistical comparison, the R software environment for statistical computing 
and graphics (R Development Core Team, 2007) was used with R-scripts for Mann-
Whitney U-test (III). The Mann-Whitney U-test is a non-parametric signifi cance test for 
evaluating the equality of population medians among two groups.
In Study IV, the preliminary data analysis was done using Mann-Whitney U-test 
(data not shown) as described above, whereas the fi nal analyses were conducted using 
statistical programming language R 2.6.2 (R Development Core Team, 2008) and 
standard mixed-effect linear models to test the effect of time, IBS subtype and age. The 
model selection was based on F-tests, and the inference from the estimated models was 
based on standard F-tests and t-tests. Furthermore, using data from all 14 real-time PCR 
assays in Study IV, a principal component analysis (PCA) and hierarchical clustering 
(data not shown) were executed to visualize the data and to study the similarities between 
samples, respectively.
3.6 Percent G+C profi ling of bacterial genomic DNA (III)
The %G+C profi ling and fractioning of the faecal bacterial DNA samples were done 
according to Holben and Harris (1995) at Danisco Innovation (Kantvik, Finland). 
Samples were pooled based on IBS symptom subtype (10 IBS-D, 8 IBS-C, 6 IBS-M and 
23 healthy controls) and centrifuged in a caesium chloride-bisbenzimidazole gradient. 
Thereafter, the gradient was divided into fractions at 5% G+C content intervals starting 
from the lower %G+C end of the profi le using perfl uorocarbon (fl uorinert) as a piston. 
The amount of DNA in the profi le was measured with a UV detector (A280) with 1% 
intervals (Apajalahti et al. 1998). Prior to cloning and sequencing, the %G+C fractions 
were desalted with PD-10 columns according to the manufacturer’s instructions (GE 
Healthcare Bio-Sciences AB).
3.7 Cloning and sequencing (III) 
From the fractions showing the most divergence between pooled samples in the %G+C 
profi les, 16S rRNA genes were cloned and partially sequenced. The inserts were 
amplifi ed with the minimum number of cycles giving detectable bands on agarose gel 
electrophoresis. Two separate universal 16S rRNA gene PCR primer pairs (Hicks et al. 
1992; Suau et al. 1999; Wang et al. 2002) were used, and the amplicons were cloned in 
a 1:1 molecular ratio using the Qiagen PCR Cloning Plus Kit (Qiagen).
A total of 13 824 clones were constructed and adequately stored. Of these, 4608 16S 
rRNA clones (384 clones from each clone library) were partially sequenced from the 
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5´-end of the 16S rRNA gene with a sequencing primer corresponding to the E. coli 16S 
rRNAgene positions 536–518 base pairs (bp) (Edwards et al. 1989). The sequencing was 
performed with the BigDye terminator cycle sequencing kit (Applied Biosystems, Foster 
City, CA, USA) and an ABI 3700 Capillary DNA Sequencer (GMI, Ramsey, MN, USA) 
at the DNA sequencing laboratory of the Institute of Biotechnology (Helsinki, Finland). 
After checking the quality of the sequences with a Staden program package (Staden 
et al. 2000) and excluding putative chimeras from sequences aligned with ClustalW 
(Chenna et al. 2003), the remaining 3753 sequences were deposited to the European 
Bioinformatics Institutes EMBL Nucleotide Sequence Database under the accession 
numbers AM275396-AM279148.
3.7.1 Analysing the 16S rRNA gene sequence library data (III) 
The composition and structure of the clone libraries were evaluated using several 
methods. For the assignment of sequences into operative taxonomic units (OTUs), the 
sequences were aligned using ClustalW 1.83 (Thompson et al. 1994) (FAST DNA pair-
wise alignment algorithm option, Gap penalty 3, Word size 4, Number of top diagonals 
1, Window size 1) and cut from the E. coli position 430 (totally conserved GTAAA) 
with BioEdit version 7.0.5.3 (Hall, 1999). Distance matrices were created with dnadist 
(Jukes-Cantor correction for distance) available in the Phylip 3.66 package (Felsenstein, 
2005).
The OTUs were determined with DOTUR (Schloss & Handelsman, 2005) applying 
98% similarity criteria. A representative sequence of each OTU was compared against 
the EMBL Environmental and EMBL Prokaryote DNA databases with Fasta Nucleotide 
Similarity Search (Pearson & Lipman, 1988). For taxonomic affi liation of sequences, 
the RDP II Classifi er Tool (Wang et al. 2007) in RDP release 9 (Cole et al. 2007) and a 
phylogenetic tree with a representative sequence from each OTU and reference sequences 
obtained from the EMBL sequence database were used. A distance matrix constructed as 
previously described and the neighbour program in the Phylip 3.66 package were used 
for generating the tree.
The distribution of sequences originating from different samples within individual 
OTUs was assessed using a ClustalW 1.83 alignment of all sequences from the 12 clone 
libraries constructed as described above and assigning the sequences to OTUs using 
DOTUR. Phylogenetic differences between the clone libraries were also visualized using 
an ARB alignment of all sequences (Ludwig et al. 2004). 
The ∫-LIBSHUFF program (Schloss et al. 2004), the BAPS 4.1 program for 
Bayesian analysis of genetic population structure (Corander et al. 2004; Corander & 
Tang, 2007) and the RDP II (RDP release 9) Library Compare Tool (Cole et al. 2007) 
were used for statistical comparison of clone libraries. The ∫-LIBSHUFF program 
analyses the differences in the libraries based on Good’s formula of coverage (Good, 
1953). In the Bayesian analysis, the homogeneous subgroups within the clone libraries 
were discovered using the unsupervised sequence classifi cation option of BAPS 4.1 
and further analysed with multidimensional scaling (MDS) (Seber, 1984). With MDS, 
systematic differences in the sample composition between the control and the symptom 
subtype can be uncovered. The RDP II Library Compare Tool assigns the sequences 






The DNA extraction method developed by Apajalahti et al. (1998) and the QIAamp DNA 
stool mini kit (Qiagen) were compared. The aforementioned method was chosen since it 
enables the extraction of higher molecular weight genomic DNA which is required for 
successful %G+C profi ling (Figure 4). Furthermore, pure cultures of E. coli quantifi ed 
using viable count were serially diluted and analysed with real-time PCR. The real-time 
PCR results were consistent with the viable count, giving slightly higher values with a 
linear range of quantifi cation between 6.5  103 and 6.5  108 target cells quantifi ed (II, 
Figure 2). This confi rms that the extraction method used gives good recovery of bacterial 
DNA, at least in the case of E. coli-like Gram-negative bacteria.
4.2 Comparison of real-time PCR and dot-blot hybridization (I) 
To evaluate molecular methods for quantifying bacteria from faecal samples, bacterial 
groups or species were quantifi ed using dot-blot hybridization and SYBR Green I or 5´-
Figure 4. Faecal DNA extracted with two different extraction methods. Four parallel samples 
were extracted using the method described by Apajalahti et al., (1998) (lanes 2-5) and the 
QIAamp DNA stool mini kit according to the manufacturers protocol for isolating DNA from stool 
for pathogen detection (QIAgen, Hilden, Germany) (lanes 6-9). The λ/PstI Marker (Fermentas, 
Burlington, Canada) was used (lane 1). bp, base pairs.
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nuclease-based real-time PCR with 16S rRNA gene targeting primers and hybridization 
probes (Table 7). Dilution series of genomic DNA from pure cultures and faecal samples 
spiked with dilution series of test bacteria were analysed.
The sensitivity of the dot-blot hybridization method was at its best 30 ng of target 
genomic DNA which corresponds to approximately 107 target genomes (I, Table 4). 
Real-time PCR had a higher sensitivity and a linear range of amplifi cation between 0.1-1 
pg and 1-10 ng of target genomic DNA corresponding to approximately 200-400 and 2  
105-4  106 target genomes (I, Figures 2 and 4). From mixed DNA samples, the dot-blot 
hybridization and real-time PCR (both applied chemistries) could detect a 3% and 0.01% 
subpopulation, respectively (I, Figures 1 and 4). The sensitivity of the methods did not 
change when the target DNA was mixed with faecal DNA. Furthermore, quantifi cation 
of Bifi dobacterium lactis from an artifi cial sample series of faeces spiked with bacterial 
cells of the target species was successful when 3.1  107 cells had been added to 1 g of 
faeces containing approximately 1011-1012 bacterial cells.
Therefore, real-time PCR was concluded to be superior in sensitivity and applicable 
for analysis of bacteria in faecal samples. The assay design for SYBR Green I chemistry 
is less troublesome since no probe sequence within the amplifi ed area is needed.
4.3 Design of real-time PCR assays (I-IV)
Thirty-seven new real-time PCR assays for quantifying indigenous, probiotic, pathogenic 
or potentially IBS-associated bacteria from faecal samples were designed and optimized 
(Table 7). The Lactobacillus group (Heilig et al. 2002; Walter et al. 2001) and universal 
PCR primers (Nadkarni et al. 2002) used have been previously published. A linear range 
of 30-4500 to 1.9  106-6.0  106 target bacterial genomes (0.1-10 pg to 10 ng of bacterial 
genomic DNA) could be quantifi ed using SYBR Green I-based real-time PCR, making 
the quantifi cation of a 0.01% bacterial subpopulation from faecal samples possible with 
real-time PCR (II, Figure 1). In Studies III and IV, real-time PCR was applied successfully 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.4 Percent G+C profi ling, cloning and sequencing (III) 
With %G+C profi ling of a bacterial community sample, the proportional amount of 
genomic DNA of a known %G+C content can be defi ned. Profi les constituted from 
different samples can be compared with each other in a community-level analysis. When 
the pooled samples of faecal microbial DNA of IBS patients (n=10 for IBS-D, n=8 for 
IBS-C, n=6 for IBS-M) and that of healthy controls (n=23) were %G+C profi led, the 
most diverging %G+C fractions were 25-30%, 40-45% and 55-60% (III, Figure 1). As 
the observed differences may be due to a number of bacterial species with corresponding 
proportional genomic G+C content, the above-mentioned diverging fractions were 
selected for subsequent cloning and sequencing of the 16S rRNA gene.
A total of 3753 high-quality sequences, covering approximately 450 bp from the 
5´-end of the 16S rRNA, were obtained with a sequencing success rate of 81% (Table 
8). The number of OTUs within each library varied from 45 to 119. When all the 3753 
sequences originating from the 12 analysed clone libraries were aligned together and 
analysed with DOTUR, they formed 486 phylotypes (98% similarity criteria). Fiftythree 
phylotypes (represented by 61 %G+C fraction specifi c OTUs) composed of 98 sequences 
with less than 95% similarity to any EMBL sequence were detected (Table 8).
Table 8. Clone library characteristics.
Sample Sequences OTUs1) Novel sequences2) Novel OTUs Coverage3)
Fraction %G+C 25-30
Control 319 91 9 4 86.5
IBS-M 324 108 9 8 79.6
IBS-C 291 63 5 5 88.0
IBS-D 342 70 3 3 89.5
Fraction %G+C 40-45
Control 346 119 9 8 80.6
IBS-M 327 100 11 6 84.7
IBS-C 323 90 4 3 86.7
IBS-D 318 78 3 3 87.9
Fraction %G+C 55-60
Control 311 45 14 3 92.9
IBS-M 289 61 12 9 89.3
IBS-C 291 70 6 5 86.6
IBS-D 272 50 13 4 91.9
1)DOTUR was used for the calculation of OTUs with 98% similarity criteria (Schloss & Handelsman, 
2005). 2)Sequences with less than 95% sequence similarity to other public database entries were considered 
novel. 3)The coverage of clone libraries was calculated according to Good (1953).
G+C, guanine plus cytosine; OTU, operative taxonomic unit
In %G+C fractions 25-30 and 40-45, most of the sequences affi liated with Firmicutes 
(Figure 5). Actinobacteria outnumbered Firmicutes in the highest G+C content fraction 
analysed in all samples, except IBS-D. The genera Coriobacterium and Collinsella within 
the phylum Actinobacteria were considerably more abundant among healthy volunteers 
(116 sequences) than in IBS subtype patients (six, 17 and 69 sequences in clone libraries 
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Figure 5. Affi liation of sequences derived from the 16S rRNA gene clone libraries. In fraction 
25-30% G+C, sequences were affi liated with multiple clostridial groups, whereas in fraction 40-
45% G+C, the C. coccoides group (XIVa) dominated. The highest G+C content fraction analysed 
(55-60%) contained mostly actinobacterial sequences in all samples, except the IBS-D sample. 






constructed from samples of IBS-C, IBS-D and IBS-M patients, respectively). Phylotypes 
with diverging numbers of sequences between sample types (IBS-D, IBS-M, IBS-C and 
healthy controls) were chosen as targets for real-time PCR assay design.
4.5 Comparison of sequence libraries (III)
All three statistical analyses (∫-LIBSHUFF, the RDP II Library Compare Tool and the 
Bayesian analysis of population structure) performed on the sequence data of the 12 
different libraries showed that the pooled faecal sample of healthy volunteers and the 
IBS subtypes differed from each other (III, Tables 5 and 6 and Figure 2). With the RDP 
II Library Compare Tool, signifi cant genus-level differences were seen in the genera 
Allisonella, Bacteroides, Bifi dobacterium, Butyrivibrio, Collinsella, Dorea, Eubacterium, 
Lactobacillus, Lactococcus, Roseburia, Ruminococcus and Streptococcus (III, Table 6). 
4.6 Alterations in the faecal microbiota of IBS patients (III, IV) 
To detect alterations in the GI microbiota of IBS patients at the 16S rRNA phylotype 
level, real-time PCR was used. The nine real-time PCR assays published in Study III 
were designed based on an ARB alignment of sequences data derived from IBS patients 
and healthy controls. The Collinsella aerofaciens-like, the Clostridium cocleatum 88% 
and the Coprococcus eutactus 97% phylotypes were signifi cantly (p-values ≤ 0.05) 
more abundant in control subjects’ samples (n=22) than in the IBS patients’ samples (all 
symptom subtypes, n=24) (III, Figure 3).
In Study IV, a more thorough analysis was executed. Six real-time PCR assays 
published in Study III (B. catenulatum/Bifi dobacterium pseudocatenulatum-like, C. 
cocleatum 88%, C. aerofaciens-like, C. eutactus 97%, Ruminococcus torques 91%, 
R. torques 94%) and eight novel assays (Bacteroides intestinalis-like, Butyrivibrio 
crossotus-like, Clostridium thermosuccinogenes 85%, Coprobacillus catenaformis 
91%, Ruminococcus bromii-like, R. torques 93%, Slackia faecicanis 91%, Spiroplasma 
chinense 84%) were used to compare IBS patients and healthy subjects. For statistical 
analysis of the results, relative quantities of target 16S rRNA genes were calculated 
using universal real-time PCR for estimation of the total quantity of eubacterial 16S 
rRNA genes. All three time-points were analysed from 20 IBS patients (8 IBS-D, 8 IBS-
C, and 4 IBS-M patients) and 15 healthy controls (Table 5). The C. catenaformis 91%, 
C. cocleatum 88%, C. thermosuccinogenes 85%, R. torques 91%, R. torques 93%, and 
R. bromii-like phylotypes were detected in all samples (Table 10).
In a PCA of the 14 phylotype targeting assays and three time-points (0, 3 and 6 
months), IBS-D differed signifi cantly from all other sample groups in the standard mixed-
effect linear model testing of the fi rst principal component differentiating the IBS subtypes 
(IV, Figure 1). The R. torques 94% phylotype was unique in being more predominant in 
IBS-D. In the assay-specifi c analyses, the abundances of C. thermosuccinogenes 85%, 
R. bromii, R. torques 93% and R. torques 94% phylotypes diverged between different 
IBS subtype patients and healthy subjects, showing the observed effect at all time-points 
analysed (Table 9). In addition, divergences were detected in time-point-dependent 
analyses of B. intestinalis-like, C. aerofaciens-like, C. cocleatum 88%, R. torques 91% 
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and S. chinense 84% phylotypes (IV, Supplementary Table 2). Signifi cantly lower levels 
of the C. thermosuccinogenes 85% phylotype were associated with IBS-D patients than 
IBS-M patients or healthy controls. A similar trend of a higher abundance in the IBS-M 
and a lower abundance in IBS-D subjects’ samples was observed with the B. intestinalis-
like and C. cocleatum 88% phylotype targeting assays. The B. intestinalis-like phylotype 
was detected in 83% of the samples (Table 10). Furthermore, the C. aerofaciens-like 
phylotype was least abundant in the IBS-D patients’ samples at the fi rst two time-
points analysed. On the other hand, the R. torques 94% phylotype was detected with 
a signifi cantly higher abundance in IBS-D subjects’ samples than in healthy controls’ 
samples independent of the time-point analysed (Table 9).
Table 9. Average number of 16S rRNA gene copies detected with real-time PCR assays relative 
to the universal real-time PCR results.
Real-time PCR assay Control IBS-C IBS-D IBS-M
Bacteroides intestinalis-like -4.851) -4.71 -5.8 -3.46
Bifi dobacterium catenulatum/
Bifi dobacterium pseudocatenulatum-like -4.1 -5.63 -5.42 -4.4
Butyrivibrio crossotus-like -6.2 -6.5 -7.34 -6.04
Clostridium cocleatum 88% -1.7 -2.36 -2.69 -0.72
Clostridium thermosuccinogenes 85% -3.33*2) -3.7 -4.08*† -3.08†
Cobrobacillus catenaformis 91% -4.72 -4.41 -4.79 -4.71
Collinsella aerofaciens-like -2.45 -2.9 -4.63 -1.73
Coprococcus eutactus 97% -5.44 -5.91 -6.55 -4.09
Ruminococcus bromii-like -3.69* -1.61* -3.4 -2.08
Ruminococcus torques 91% -3.13 -2.87 -2.58 -2.83
Ruminococcus torques 93% -2.41* -2.61 -2.65 -2.92*
Ruminococcus torques 94% -4.02* -3.39 -2.43* -3.82
Slackia faecicanis 91% -5.53 -5.6 -6.22 -4.01
Spiroplasma chinense 84% -5.62 -5.36 -6.51 -5.7
 1)Values are presented as log10 averages from three time-points (0, 3 and 6 motnhs). 2)Signifi cantly differing values 
(p-value ≤ 0.05) between sample types are denoted with an asterisk (*) or cross (†).
IBS-C, constipation-predominant irritable bowel syndrome; IBS-D, diarrhoea-predominant irritable bowel syndrome; 
IBS-M, mixed-subtype irritable bowel syndrome; real-time PCR, real-time polymerase chain reaction. 
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Bacteroides intestinalis-like 13 6 6 4
Bifi dobacterium catenulatum/
Bifi dobacterium pseudocatenulatum-like 14 5 7 4
Butyrivibrio crossotus-like 7 0 3 2
Clostridium cocleatum 88% 15 8 8 4
Clostridium thermosuccinogenes 85% 15 8 8 4
Cobrobacillus catenaformis 91% 15 8 8 4
Collinsella aerofaciens-like 15 7 7 4
Coprococcus eutactus 97% 9 2 3 3
Ruminococcus bromii-like 15 8 8 4
Ruminococcus torques 91% 15 8 8 4
Ruminococcus torques 93% 15 8 8 4
Ruminococcus torques 94% 14 8 7 4
Slackia faecicanis 91% 8 3 4 4
Spiroplasma chinense 84% 9 2 5 2
IBS-C, constipation-predominant irritable bowel syndrome; IBS-D, diarrhoea-predominant irritable bowel syndrome; 




The intestinal microbiota is an extremely rich and dynamic microbial community 
constituted mainly of not yet cultured bacteria, and therefore, molecular methods are 
needed for microbial community analysis (Zoetendal et al. 2008). Our study shows that 
real-time PCR is applicable for analysis of faecal samples and provides a valuable set 
of real-time PCR primers for quantifying human intestinal bacteria using a molecular 
approach. Real-time PCR has since become a popular method for quantifying intestinal 
bacteria (Carey et al. 2007), and the primers presented here have been successfully 
applied for analysis of faecal microbiota in IBS-related (Kajander et al. 2007; Malinen 
et al. 2005) and other studies (Balamurugan et al. 2008; Firmesse et al. 2007; Songjinda 
et al. 2007).
IBS, a common functional GI disorder of unknown aetiology, has a substantial 
impact on the patient’s quality of life (Hillilä & Färkkilä, 2004; Longstreth et al. 2006). 
The diagnosis of IBS is still symptom-based and the symptoms vary between patients 
and over time, resulting in a heterogeneous group of IBS patients (Longstreth et al. 
2006; Thompson et al. 1999). Therefore, we determined the bacterial 16S rRNA gene 
phylotypes differing in abundance in the faecal samples of IBS patients and healthy 
controls. The individuality (Ley et al. 2006b; Matsuki et al. 2004; Zoetendal et al. 1998) 
and species richness (Andersson et al. 2008; Eckburg et al. 2005) of the human intestinal 
microbiota add further challenges to the identifi cation of IBS-associated 16S rRNA gene 
phylotypes. Molecular analyses at the level of the whole microbial community (%G+C 
profi ling) to groups and 16S rRNA gene phylotypes of bacteria (cloning and sequencing, 
real-time PCR) were applied on faecal samples of IBS patients and healthy controls. 
Taking into account the heterogeneous nature of the sample material and the health 
condition in question, the results attained should be confi rmed with multiple independent 
sample panels and subjects with separate IBS symptoms (i.e. diarrhoea, constipation) 
but not the whole syndrome. In addition, analysing the microbiota of mucosal samples 
would be worthwhile since faecal and colonic mucosal microbiotas differ (Zoetendal et 
al. 2002). However, colonoscopy is required to obtain mucosal samples, placing an extra 
burden on study subjects. It should also be noted that these results give no indication as 
to whether the observed alterations in the intestinal microbiotas of IBS patients are a 
causative agent in IBS aetiology or merely a result of the altered gut environment.
Moreover, with faeces as sample material, inter- and intra-individual variation is 
expected (Eckburg et al. 2005; Rajilić-Stojanović, 2007; Zoetendal et al. 1998). Therefore, 
with the aim of focusing on IBS related alterations, IBS patients were subgrouped based 
on symptom subtype (Thompson et al. 1999), and the samples were pooled accordingly 
prior to %G+C profi ling and cloning and sequencing (III). The symptoms were assessed 
at the beginning of the study, making the fi rst time-point the most reliable for symptom 
subgrouping. Since IBS is chronic in nature, it is unlikely that a substantial number of 
study subjects would have ceased to have symptoms altogether. The quantitative real-
time PCR analyses (III and IV) were done using individual samples to obtain statistical 




Other aspects to consider are the differences in abundances and molecular features of 
bacterial species in faecal samples that cause biases during sample handling and nucleic 
acid extraction, especially for quantitative data (Salonen et al. 2009). In the present 
study, the nucleic acid extraction method described by Apajalahti et al., (1998) was 
chosen due to %G+C profi ling, and all samples were extracted using this method. The 
applied protocol produces a high yield of comparably high molecular weight genomic 
DNA necessary for %G+C density gradient centrifugation. The faecal phylotypes could 
possibly be more accurately quantifi ed if the extraction method applied is verifi ed to lyse 
the different bacterial species with a minimum bias (Salonen et al. 2009). In our study, 
such verifi cation was not executed, but the quantities of predominant bacteria detected 
in Study II were in good agreement with previous estimations (Franks et al. 1998; Suau 
et al. 2001; Wilson & Blitchington, 1996). The main goal in Studies III and IV was to 
perform comparative analyses rather than to defi ne actual quantities.
Three subjects aged over 57 years grouped separately in a hierarchical cluster 
analysis of the 14 real-time PCR assays comparing IBS patients and healthy controls 
(data not shown). This is in accordance with earlier fi ndings of ageing affecting the 
composition of the intestinal microbiota (Collado et al. 2007; Hayashi et al. 2003). 
Age had a signifi cant effect in the R. torques 91% and a trend in the B. catenulatum/B. 
pseudocatenulatum-like assay results (data not shown). In the PCA done on the same 
data comparing IBS patients with healthy controls, the effect of age was not seen in the 
fi rst two principal components. In similar studies in the future, limiting the age range of 
recruited subjects is advisable.
In the %G+C profi ling, three fractions (%G+C 25-30, 40-45 and 55-60) were 
found to differ between IBS patients and healthy controls. In %G+C fraction 55-60, 
these differences were supported by the sequence data: the healthy control sample, 
which had the highest amount of genomic microbial DNA in %G+C fraction 55-60, 
was also most abundant with high G+C actinobacterial sequences among the 16S rDNA 
clone libraries. However, the distribution of genomic DNA into %G+C fractions is 
not absolute, and some leakage between fractions may occur. Crohn’s disease patients 
have been investigated using %G+C profi ling, but the DNA fractions were not further 
analysed, and no association with Crohn’s disease could be seen in the %G+C profi les 
(Dicksved et al. 2008).
The clone libraries of IBS symptom subtypes and healthy controls differed from 
each other according to ∫-LIBSHUFF (Schloss et al. 2004), the BAPS 4.1 program for 
Bayesian analysis of genetic population structure (Corander et al. 2004; Corander & 
Tang, 2007) and the RDP II (RDP release 9) Library Compare Tool (Cole et al. 2007). 
In the HITChip analysis by Rajilić-Stojanović (2007), the overall microbiota of IBS 
patients, without subgrouping according to IBS symptom subtype, was found to differ 
from that of healthy volunteers. In this study, the cloning and sequencing of three %G+C 
fractions indicated a distinctive intestinal microbiota within each IBS symptom subtype, 
but the clone libraries analysed did not cover the complete microbiota, and no replicate 
clone libraries were analysed.
In the clone libraries, the genera Coriobacterium and Collinsella within the phylum 
Actinobacteria were considerably more abundant among healthy volunteers than among 
IBS subtype patients. The fi nding was further verifi ed with a real-time PCR assay 
targeting C. aerofaciens in Studies III and IV. Higher levels of Actinobacteria have 
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previously been associated with healthy controls in a metagenomic study on Crohn’s 
disease patients (Manichanh et al. 2006), and C. aerofaciens has been associated with a 
low risk of colon cancer (Moore & Moore, 1995). Since the samples were pooled from 
multiple individuals, the divergences found between clone libraries could be due to one 
or a few subjects distorting the composition of the pooled sample. This was proven to be 
the case for a Lactobacillus farciminis-like phylotype quantifi ed with real-time PCR from 
individual samples in Study III. No replicate clone libraries could be analysed due to the 
high cost of sequencing at the time of the study. The clone libraries were, however, an 
essential tool for the design of real-time PCR assays targeting alterations in the intestinal 
microbiotas of IBS patients. The assays were done with individual samples.
Of the 32 tested (data not shown) real-time PCR assays designed from the IBS-
related clone library sequences, this sudy resulted in a set of 14 assays with potentiality 
for differentiating the IBS-D subtype from the other IBS subtypes and the healthy controls 
in a multivariate analysis. This is in good accordance with other studies showing the 
uniqueness of IBS-D subtype in comparison to other IBS subtypes (Gecse et al. 2008; 
Roka et al. 2007). Therefore, it would be advisable in future studies to take the IBS 
symptom subtype into account.
The real-time PCR assay design in this study was based on clone library phylo-
types, which makes it diffi cult to compare our results with previously published fi ndings. 
Within the phylotypes showing divergence between sample types throughout the six 
month survey, C. thermosuccinogenes 85% represents a yet unknown fi rmicute within 
the human GI microbiota having a strong association with IBS-M and healthy controls 
as compared with patients suffering from IBS-D. The target sequence of the C. thermo-
succinogenes 85% assay has previously been detected by Eckburg et al. (2005) and Gill 
et al. (2006). 
The R. bromii-like phylotype was associated with IBS-C patients. Ruminococcus 
bromii related phylotypes have been shown to increase with a diet high in resistant 
starch (Abell et al. 2008). In the present study, however, it is more likely that the slowed 
colonic transit among IBS-C patients, rather than a dietary effect, resulted in an environ-
ment favourable for the quantifi ed phylotype.
The R. torques 94% phylotype was associated with IBS-D in PCA and assay spe-
cifi c-analysis. The bacterium Ruminococcus torques is a resident member of the human 
GI microbiota capable of degrading mucin (Hoskins et al. 1985), and it has earlier been 
associated with the mucosa of Crohn’s disease patients (Martinez-Medina et al. 2006). 
Furthermore, the specifi c phylotype target sequence of the R. torques 94% assay has pre-
viously been detected in several studies (Hayashi et al. 2002b; Ley et al. 2006b; Mai et 
al. 2006) and found to be associated with Crohn’s disease (Frank et al. 2007). The altera-
tions observed with C. thermosuccinogenes 85% and R. torques 94% assays were stable 
throughout the six-month survey. The C. thermosuccinogenes 85% phylotype comprised 
0.05%, 0.08% and 0.01% of the faecal microbial population in the control, IBS-M and 
IBS-D samples, respectively, and the R. torques 94% phylotype comprised 0.37% and 
0.01% of the IBS-D and control samples, respectively. The R. torques 93% phylotype 
was associated with the control subjects compared with IBS-M patients. 
The hypothesis of the intestinal microbiota having an aetiological role in IBS 
is supported by the occurrence of IBS symptoms after an infectious gastroenteritis 
(Rodriguez & Ruigomez, 1999), the elevated amount of non-endogenous serine protease 
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in faecal supernatants of IBS-D patients capable of causing IBS-like symptoms in mice 
(Gecse et al. 2008), the higher levels of fl agellin antibodies in IBS patients (Schoepfer 
et al. 2008) and the effectiveness of probiotic treatment in stabilizing the microbiota 
(Kajander et al. 2008). Previously, alterations at whole-community level (Rajilić-
Stojanović, 2007) and evidence of divergences in specifi c microbial groups, species and 
phylotypes (Malinen et al. 2005; Maukonen et al. 2006; Rajilić-Stojanović, 2007) have 
been detected. The studies by Malinen et al. (2005) and Maukonen et al. (2006) were 
conducted using the same samples as in this study. 
In the present study, the use of IBS-associated 16S rRNA gene sequence libraries for 
real-time PCR assay design was rewarding, as the IBS-D subtype could be differentiated 
by quantifying only 14 phylotypes, and phylotype-specifi c alterations stable over time 




a) Real-time PCR proved to be a sensitive and reliable method for quantifying bacteria 
from faecal samples, with a linear range of quantifi cation between 6  103 and 
6 108 bacterial cells.
b) An extensive set of real-time PCR assays targeting intestinal bacteria or phylotypes 
was designed. All assays presented here have been successfully applied to analyses 
of faecal samples. The assays based on bacterial reference strain 16S rRNA gene 
sequences are applicable to quantifying approximately 300 human intestinal species. 
They were published as the fi rst thorough set of real-time PCR assays for quantifying 
the human intestinal microbiota. 
c) The clone libraries constructed from IBS symptom subtypes and healthy controls 
were found to diverge from each other, but no replicate clone libraries were analysed. 
The clone libraries provided a valuable set of sequence data for designing real-
time PCR assays, specifi cally targeting IBS-associated alterations in the intestinal 
microbiota.
d) Clone library sequence-based real-time PCR assays applied on individual samples 
were able to detect statistically signifi cant differences in faecal microbiotas between 
IBS patients grouped according to symptom subtype and healthy controls. Whether 
the observed alterations are a causative agent in IBS aetiology or merely a result of 
the altered gut environment remains unknown. The IBS-D subtype deviated from the 
other IBS subtypes and healthy controls in a multivariate analysis of 14 quantifi ed 
16S rRNA gene phylotypes. A novel clostridial 16S rRNA gene phylotype, C. 
thermosuccinogenes 85%, was more strongly associated with IBS-M and healthy 
controls than with IBS-D, and a R. torques 94% phylotype was more abundant in the 
faecal microbiota of IBS-D patients than in that of healthy controls. Furthermore, 
an elevated abundance of a R. bromii-like phylotype and a decreased abundance of 
a R. torques 93% phylotype in compared to control subjects were associated with 
IBS-C and IBS-M patients, respectively. All of these phylotype-specifi c alterations 




This study yelded a valuable set of real-time PCR assays for evaluation of the human 
intestinal microbiota in general and in association with IBS or other intestinal health 
disturbances. The real-time PCR methodology is highly sensitive and has a comparatively 
wide range of nucleic acid-based quantifi cation.
Several quantitative alterations were detected in the GI microbiotas at the 16S 
rRNA gene phylotype level between IBS patients subgrouped according to symptom 
subtype and healthy controls. The observed alterations should be tested with novel IBS 
patient sample panels and with subjects suffering from diarrhoea or constipation but not 
fulfi lling IBS criteria.
Our results support the hypothesis of intestinal bacteria having a role in IBS, and 
the diverging phylotypes warrant further studies on their potential use in IBS diagnosis, 
therapeutic trial follow-up and host-microbe interactions. For more effi cient diagnostic 
and therapeutic trial follow-up purposes, a higher through-put methodology, e.g. 
microarray technology or possibly multiplexing of real-time analyses, is necessary. To 
enable studies on host-microbe interactions of the yet uncultivated 16S rRNA phylotypes 
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